title: Perfluorodecalin-enriched fibrin matrix for human islet culture.
abstract: Disruption of microenvironment and decrease in oxygen supply during isolation and culture lead to pancreatic islet injury and their poor survival after transplantation. This study aimed to create a matrix for culturing islets, using fibrin as scaffold and perfluorodecalin as oxygen diffusion enhancing medium. Human pancreatic islets were divided in four groups: control, islets cultured in fibrin, islets in fibrin containing non-emulsified perfluorodecalin, and finally islets in fibrin supplemented with emulsified perfluorodecalin. After an overnight culture, cell damage (viability, proinsulin and insulin unregulated release, apoptosis (caspase-3 activation), secretory function, and presence of hypoxia markers (HIF-1a and VEGF expression) were assessed. Islets cultured in a matrix, had similar islet viability to controls (no matrix) but decreased levels of active caspase-3 and unregulated hormone release, but high level of hypoxia markers expression. Although the supplementation of fibrin with non-emulsified perfluorodecalin improves secretory response, there was no decrease in hypoxia markers expression. In contrast, emulsified perfluorodecalin added to the matrix improved islet function, islet viability and maintained level of hypoxia markers similar to control. Fibrin matrix supplemented with emulsified perfluorodecalin can provide a beneficial physical and chemical environment for improved pancreatic human islet function and viability in vitro.
authors: Islet Transplant Research Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. elisamaillard@nds.ox.ac.uk
authors: Elisa
authors: E
authors: Maillard
authors: Maciej T
authors: MT
authors: Juszczak
authors: Anne
authors: A
authors: Clark
authors: Stephen J
authors: SJ
authors: Hughes
authors: Derek R W
authors: DR
authors: Gray
authors: Paul R V
authors: PR
authors: Johnson
mesh_terms: D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism*; D005337:Fibrin / Q000494:pharmacology*; D005466:Fluorocarbons / Q000494:pharmacology*; D006801:Humans; D000860:Hypoxia / Q000473:pathology; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D009924:Organ Culture Techniques / Q000379:methods*; D021381:Protein Transport / Q000187:drug effects; D014022:Tissue Survival / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D005466:Fluorocarbons; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007328:Insulin; D042461:Vascular Endothelial Growth Factor A; C008805:perfluorodecalin; D005337:Fibrin